一个复杂的病例,胜利地治疗了抗N-甲基D-酸盐 (NMDA) 受体脑炎
Amer Abu-Shanab1, Raymart Macasaet1, Ahmed B Mohd2
1Department of Internal Medicine, Monmouth Medical Center, Long Branch, USA.
Cureus
|March 4, 2025
概括
抗N-甲基D-酸盐 (NMDA) 受体脑炎是一种自身免疫性疾病,可引起严重的神经精神症状. 通过自身抗体检测及时诊断,及时治疗免疫疗法和瘤切除对于患者的康复至关重要.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 抗N-甲基D-酸盐 (NMDA) 受体脑炎是一种罕见的自身免疫神经系统疾病.
- 它的特征是免疫球蛋白G (IgG) 抗体向NMDA受体的NR1亚单元.
- 卵巢瘤是一种常见的触发因素,特别是在年轻女性中,呈现出精神和神经症状.
更多相关视频
07:20A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
9.8K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
418
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
267
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
267
Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
